Prostaglandins E1 and E2 analogues ameliorate mucosal injury secondary to distal colonic obstruction

Journal of Investigative Surgery

Volumn 16, Issue 5, 2003, Pages 283-288

  Gurleyik, Gunay ^a,d   Ozturk, Erol ^a   Gurleyik, Emin ^b   Aker, Fugen ^c   Aktekin, Ali ^a   Ozkara, Selvinaz ^c   Saglam, Abdullah ^a  

^a HAYDARPASA NUMUNE EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^b ABANT IZZET BAYSAL UNIVERSITY   (Turkey)

^c Haydarpa a Numune Teaching Hospital   (Turkey)

^d NONE   (Turkey)

Author keywords

Colonic obstruction; Large bowel; Mucosal injury; Prostaglandins

Indexed keywords

MISOPROSTOL; PROSTAGLANDIN E1 DERIVATIVE; PROSTAGLANDIN E2; PROSTAGLANDIN E2 DERIVATIVE; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CECUM; COLON INJURY; COLON MUCOSA; COLON OBSTRUCTION; CONTROLLED STUDY; DESCENDING COLON; HISTOPATHOLOGY; INTESTINE WALL; LIGATION; MALE; MEASUREMENT; NONHUMAN; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RAT; RAT STRAIN; SCORING SYSTEM; SIGMOID; STATISTICAL ANALYSIS; THICKNESS;

EID: 0242636381     PISSN: 08941939     EISSN: None     Source Type: Journal    
DOI: 10.1080/08941930390230423     Document Type: Article

References (13)

1. Fischer JE, Nussbaum MS, Chance WT, Lucette F. Manifestations of gastrointestinal disease. In: Schwartz SI, ed., Principles of Surgery, 7th ed. New York: McGraw-Hill; 1999:1033-1081.
2. Tibble JA, Sigthorsson G, Foster R, Bjarnason I. Comparison of the intestinal toxicity of celecoxib, a selective COX-2 inhibitor, and indomethacin in the experimental rat. Scand J Gastroenterol. 2000;35:802-807.
3. Mizoguchi H, Hase S, Tanaka A, Takeuchi K. Lack of small intestinal ulcerogenecity of nitric oxide-releasing indomethacin, NCX 530 in rats. Aliment Pharmacol Ther. 2001;115:257-267.
4. Schweizer E, Gassel A, Deltz D, Schroeder P. Morphologic and histologic alterations after small bowel transplantation: A comparison of different perfusion solutions. Transplant Proc. 1992;124:1087.
5. Deitch EA, Bridges WM, Ma JW, Ma L, Berg RD, Specian RD. Obstructed intestine as a reservoir for systemic infection. Am J Surg. 1990;159:394-401.
6. Antequera R, Bretana A, Cirac A, Brito A, Romera MA, Zapata R. Disruption of the intestinal barrier and bacterial translocation in an experimental model of intestinal obstruction. Acta Cient Venez. 2000;51:18-26.
7. Akyildiz M, Ersin S, Oymaci E, Dayangac M, Kapkac M, Alkanat M. Effects of somatostatin analogues and vitamin C on bacterial translocation in an experimental intestinal obstruction model of rats. J Invest Surg. 2000;13:169-173.
8. Belyansky LS, Sayenko YF, Furmarov JA, Churilova TJ. Bacterial translocation as a cause for septic complications in obstructive colonic ileus. Acta Chir Belg. 2002;102:75-77.
9. Fukushima R, Alexander JW, Gianotti R, Pyles T, Ogle CK. Bacterial translocation-related mortality may be associated with neutrophil-mediated organ damage. Shock. 1995;3:323-328.
10. Fukushima R, Gianotti R, Alexander JW, Pyles T. The degree of bacterial translocation is a determinant factor for mortality after burn injury and is improved by prostaglandin analogs. Ann Surg. 1992;216:438-444.
11. Gionnetti R, Alexander JW, Pyles T, Fukushima R, Babcock GF. Prostaglandin E1 analogues misoprostol and enisoprost decrease microbial translocation and modulate the immune response. Circ Shock. 1993;40:243-249.
12. Hirata I, Murano M, Nitta M, Sasaki S, Toshina K, Maemura K, Katsu K. Estimation of mucosal inflammatory mediators in rat DSS-induced colitis. Possible role of PGE(2) in protection against mucosal damage. Digestion. 2001;63:73-80.
13. Helton WS, Garcia R. Oral prostaglandin E2 prevents gut atrophy during intravenous feeding but not bacterial translocation. Arch Surg. 1993;128:178-184.